Allos Therapeutics to Report Fourth Quarter and Full Year 2011 Results on March 6, 2012
22 February 2012 - 12:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that the
Company will report its financial results for the fourth quarter
and full year ended December 31, 2011 on Tuesday, March 6, 2012,
after the financial markets close. Following the release of the
financial results, Allos management will provide a corporate update
via conference call and audio webcast. Access to the conference
call and webcast may be obtained as follows:
Time: 4:30 PM ET / 2:30 PM MT
Date: Tuesday, March 6, 2012
Dial-in: 1-877-941-0843 (U.S.) or +480-629-9819 (Canada and
international)
Webcast: www.allos.com (homepage and “Investors - Presentations
and Events” section)
A recorded rebroadcast will be available for interested parties
unable to attend the live conference call by dialing 1-800-406-7325
(domestic) or +1-303-590-3030 (international) and using passcode
4515372#. Webcast and telephone replays of the conference call will
be available approximately two hours after the completion of the
call through March 20, 2012.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYN® (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is
approved in the U.S. for the treatment of patients with relapsed or
refractory peripheral T-cell lymphoma, or PTCL. For additional
information, please visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's
Quarterly Report on Form 10-Q for the quarter ended September 30,
2011 and in the Company's other periodic reports and filings with
the Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in the presentation. All forward-looking
statements are based on information currently available to the
Company on the date thereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of these
presentations, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics News Articles